1-(2-Hydroxymorpholin-4-yl)ethanone

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 恶嗪烷类
• 英文名称: 1-(2-Hydroxymorpholin-4-yl)ethanone
• 英文别名: 1-(2-hydroxymorpholin-4-yl)ethanone
• 化学式: C₆H₁₁NO₃
• 分子量: 145.16
• InChiKey: YKOPPBHXHIEIRA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.2
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  49.8
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• DEUTERIUM SUBSTITUTED FUMARATE DERIVATIVES
  申请人：Biogen MA Inc.

  公开号：EP2934503A1

  公开（公告）日：2015-10-28
• [EN] DEUTERIUM SUBSTITUTED FUMARATE DERIVATIVES<br/>[FR] DÉRIVÉS DE FUMARATE SUBSTITUÉS PAR DU DEUTÉRIUM
  申请人：BIOGEN IDEC INC

  公开号：WO2014100728A1

  公开（公告）日：2014-06-26

  Provided is a compound of formula (I), or a pharmaceutically acceptable salt thereof. Also provided is a method of treating, prophylaxis, or amelioration of a disease, comprising administering to a subject in need of treatment for the disease an effective amount of a compound of formula (I) described herein. In one embodiment, the method is a neurodegenerative disease, such as multiple sclerosis, amyotrophic lateral sclerosis, Parkinson's disease, Huntington's disease, or Alzheimer's disease.
• [EN] sGC STIMULATORS<br/>[FR] STIMULATEURS DE SGC
  申请人：IRONWOOD PHARMACEUTICALS INC

  公开号：WO2016044445A2

  公开（公告）日：2016-03-24

  The present patent application discloses at least the compounds according to Formula (Ia) and Formula (Ib) shown below, or pharmaceutically acceptable salts thereof, wherein ring D, ring A, JB, n, J, RC1, RC2, Z1, Z2, W, X, Y1, Y2, JF and R9 are as defined herein.